Cargando…
Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study
OBJECTIVES: To assess the impact of extra-articular spondyloarthritis (SpA) manifestations (anterior uveitis, psoriasis and inflammatory bowel disease (IBD)), and of comorbidities, on tumour necrosis factor alpha inhibitor (TNFi) drug retention in ankylosing spondylitis (AS). METHODS: We identified...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203098/ https://www.ncbi.nlm.nih.gov/pubmed/30402269 http://dx.doi.org/10.1136/rmdopen-2018-000762 |
_version_ | 1783365810566201344 |
---|---|
author | Lindström, Ulf Olofsson, Tor Wedrén, Sara Qirjazo, Ilia Askling, Johan |
author_facet | Lindström, Ulf Olofsson, Tor Wedrén, Sara Qirjazo, Ilia Askling, Johan |
author_sort | Lindström, Ulf |
collection | PubMed |
description | OBJECTIVES: To assess the impact of extra-articular spondyloarthritis (SpA) manifestations (anterior uveitis, psoriasis and inflammatory bowel disease (IBD)), and of comorbidities, on tumour necrosis factor alpha inhibitor (TNFi) drug retention in ankylosing spondylitis (AS). METHODS: We identified all bio-naïve patients with AS starting a first ever TNFi July 2006 to December 2015 from the Swedish Rheumatology Quality register and followed these from treatment start through December 2015. We determined the presence of extra-articular SpA-manifestations, comorbidities (cardiovascular disease, affective disease, diabetes, malignancies, chronic lung disease and kidney disease) and socioeconomic status before TNFi start, through linkage to five other national registers, and calculated, for each factor, crude and adjusted HRs for discontinuing the TNFi. RESULTS: 2577 patients with AS (71% men) started a first TNFi during the study period. 27% had a history of anterior uveitis, 6% psoriasis and 7% IBD. Anterior uveitis was associated with a superior TNFi drug retention (HR 0.72; 0.62 to 0.83), psoriasis with an inferior (HR 1.48; 1.18 to 1.86), whereas IBD did not affect TNFi drug retention. The effect of the SpA manifestations on TNFi drug retention was of a similar magnitude to that of the comorbidities. CONCLUSIONS: In AS, anterior uveitis and psoriasis, but not IBD, affect TNFi drug retention. Possible explanations include differential effects of TNFi on these extra-articular SpA manifestations, or inherent differences in AS, associated with the inflammatory phenotype. Further, comorbidities and socioeconomy affect TNFi drug retention to a similar magnitude as the SpA manifestations, and should, as such, receive due attention in clinical practice. |
format | Online Article Text |
id | pubmed-6203098 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-62030982018-11-06 Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study Lindström, Ulf Olofsson, Tor Wedrén, Sara Qirjazo, Ilia Askling, Johan RMD Open Spondyloarthritis OBJECTIVES: To assess the impact of extra-articular spondyloarthritis (SpA) manifestations (anterior uveitis, psoriasis and inflammatory bowel disease (IBD)), and of comorbidities, on tumour necrosis factor alpha inhibitor (TNFi) drug retention in ankylosing spondylitis (AS). METHODS: We identified all bio-naïve patients with AS starting a first ever TNFi July 2006 to December 2015 from the Swedish Rheumatology Quality register and followed these from treatment start through December 2015. We determined the presence of extra-articular SpA-manifestations, comorbidities (cardiovascular disease, affective disease, diabetes, malignancies, chronic lung disease and kidney disease) and socioeconomic status before TNFi start, through linkage to five other national registers, and calculated, for each factor, crude and adjusted HRs for discontinuing the TNFi. RESULTS: 2577 patients with AS (71% men) started a first TNFi during the study period. 27% had a history of anterior uveitis, 6% psoriasis and 7% IBD. Anterior uveitis was associated with a superior TNFi drug retention (HR 0.72; 0.62 to 0.83), psoriasis with an inferior (HR 1.48; 1.18 to 1.86), whereas IBD did not affect TNFi drug retention. The effect of the SpA manifestations on TNFi drug retention was of a similar magnitude to that of the comorbidities. CONCLUSIONS: In AS, anterior uveitis and psoriasis, but not IBD, affect TNFi drug retention. Possible explanations include differential effects of TNFi on these extra-articular SpA manifestations, or inherent differences in AS, associated with the inflammatory phenotype. Further, comorbidities and socioeconomy affect TNFi drug retention to a similar magnitude as the SpA manifestations, and should, as such, receive due attention in clinical practice. BMJ Publishing Group 2018-10-15 /pmc/articles/PMC6203098/ /pubmed/30402269 http://dx.doi.org/10.1136/rmdopen-2018-000762 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Spondyloarthritis Lindström, Ulf Olofsson, Tor Wedrén, Sara Qirjazo, Ilia Askling, Johan Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study |
title | Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study |
title_full | Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study |
title_fullStr | Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study |
title_full_unstemmed | Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study |
title_short | Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study |
title_sort | impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first tnf-inhibitor in ankylosing spondylitis: a population-based nationwide study |
topic | Spondyloarthritis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203098/ https://www.ncbi.nlm.nih.gov/pubmed/30402269 http://dx.doi.org/10.1136/rmdopen-2018-000762 |
work_keys_str_mv | AT lindstromulf impactofextraarticularspondyloarthritismanifestationsandcomorbiditiesondrugretentionofafirsttnfinhibitorinankylosingspondylitisapopulationbasednationwidestudy AT olofssontor impactofextraarticularspondyloarthritismanifestationsandcomorbiditiesondrugretentionofafirsttnfinhibitorinankylosingspondylitisapopulationbasednationwidestudy AT wedrensara impactofextraarticularspondyloarthritismanifestationsandcomorbiditiesondrugretentionofafirsttnfinhibitorinankylosingspondylitisapopulationbasednationwidestudy AT qirjazoilia impactofextraarticularspondyloarthritismanifestationsandcomorbiditiesondrugretentionofafirsttnfinhibitorinankylosingspondylitisapopulationbasednationwidestudy AT asklingjohan impactofextraarticularspondyloarthritismanifestationsandcomorbiditiesondrugretentionofafirsttnfinhibitorinankylosingspondylitisapopulationbasednationwidestudy |